TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23889312
Drug: Adapted non‐Hodgkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance (Arm B1)
Study: 23889312
Drug: Adapted non‐Hodgkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance and intensification (Arm B2)
Study: 16501393
Drug: Inpatient/Residential treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient/Residential treatment
Study: 16501393
Drug: Any Treatment
Normalized name: Acanya
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any Treatment
Study: 16501393
Drug: Residential/Inpatient treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential/Inpatient treatment
Study: 15255797
Drug: Rectal methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal methadone (10 mg d(5)‐methadone‐HCl rectally)
Study: 15255797
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (10 mg d(0)‐methadone orally)
Study: 11359593
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 ketamine
Study: 11359593
Drug: 0.1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg.kg‐1 morphine
Study: 8324915
Drug: Carbidopa 100
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa 100 mg
Study: 3540308
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment program 1
Study: 3540308
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment program 2
Study: 3540308
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment program 3
Study: 27454264
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen alone (800 mg at induction, 800 mg every 6 hours for up to 5 days)
Study: 27454264
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen (800 mg at induction, 800 mg every 6 hours for up to 5 days) + IV acetaminophen (1000 mg at closure, 800 mg + 1000 mg every 6 hours for up to 5 days)
Study: 27454264
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen alone
Study: 27454264
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen + IV acetaminophen
Study: 23845320
Drug: Graduated compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graduated compression stockings and subcutaneous injection of unfractionated heparin (unless contraindicated)
Study: 23845320
Drug: Antipsychotic dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic dosage
Study: 19863495
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL of milk fermented with Lactobacillus paracasei, ssp. paracasei F19, Lactobacillus acidophilus La5, and Bifidobacterium lactis Bb12 (Cultura; active)
Study: 18829508
Drug: Docetaxel (60-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60-75 mg/m² every 21 days) + Atrasentan (10 mg daily starting on day 3)
Study: 16485512
Drug: Long-acting lipophilic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting lipophilic ACE-inhibitors
Study: 12452468
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg gemeprost vaginal pessary every 6 hours for 18 hours
Study: 12452468
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 200 microg misoprostol tablets vaginally followed by 2 x 200 microg misoprostol tablets orally every 3 hours for 12 hours
Study: 10599982
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (fluvastatin 40 mg/d and gemfibrozil)
Study: 7547039
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml preload of crystalloid solution
Study: 7547039
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml preload of crystalloid solution
Study: 1743319
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone 300 mg
Study: 1743319
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone 200 mg
Study: 1743319
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (300 mg, 200 mg, placebo)
Study: 1743319
Drug: Endogenous E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous E2 and treatment P concentrations
Study: 21936751
Drug: Compensation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compensation of $5 for weekly urine drug screens and self-reported drug use information, $75 for extensive assessments at weeks 4, 8, and 12
Study: 8923916
Drug: Transvaginal ultrasonography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal ultrasonography for evaluating endometrial grades and hormone levels (progesterone and estradiol).
Study: 2025473
Drug: hyperbaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric 0.5% bupivacaine 2.5 ml at L2-3 (n = 20)
Study: 2025473
Drug: hyperbaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric 0.5% bupivacaine 2.5 ml at L4-5 (n = 20)
Study: 7044682
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin prophylaxis (5000 U subcutaneously twice daily)
Study: 24429845
Drug: Secoisolariciresinol-diglycoside (SDG)
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secoisolariciresinol-diglycoside (SDG) at doses of 25, 50, 75, 86, and 172 mg
Study: 22431963
Drug: Rintatolimod (Poly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rintatolimod (Poly I: C(12)U) 400 mg twice weekly
Study: 20549835
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of asenapine (5 mg)
Study: 20549835
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of asenapine (5 mg)
Study: 20549835
Drug: Supralingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supralingual administration of asenapine (5 mg)
Study: 18257188
Drug: Acupoint-injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-injection therapy with Jingming (BL 1), Yangbai (GB 14), Sibai (ST 2), Tongziliao (GB 1), bilateral Ganshu (BL 18), and compound Danggui Injection as the principal injected medicine.
Study: 18257188
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine therapy.
Study: 18257188
Drug: Acupoint-injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-injection therapy
Study: 18257188
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine therapy
Study: 16498927
Drug: Monophasic (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic (120 ml at 2.5 ml/s)
Study: 16498927
Drug: Low-high biphasic
Normalized name: DEXTRO-CHEK LOW & HIGH CALIBRATORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-high biphasic (120 ml, first 60 ml at 2 ml/s, the other 60 ml at 2.5 ml/s)
Study: 16498927
Drug: High-low biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-low biphasic (120 ml, first 60 ml at 2.5 ml/s, the other 60 ml at 2 ml/s)
Study: 10907802
Drug: Fluoxetine (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (48 mg/day, range 10 mg to 60 mg)
Study: 8887059
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) administered both topically and intramuscularly for 15 days
Study: 1712273
Drug: Cilazapril 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1.25 to 5 mg daily
Study: 1712273
Drug: Cilazapril (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (single dose of 2.5 or 5 mg)
Study: 30738426
Drug: Ambroxol high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol high-dose (1050 mg/day)
Study: 30738426
Drug: Ambroxol low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ambroxol low-dose (525 mg/day)
Study: 30738426
Drug: Ambroxol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (both doses)
Study: 28775306
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with four doses
Study: 28775306
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with three doses
Study: 21076273
Drug: HIV-1 recombinant
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 recombinant canarypox vaccine (vCP1452)
Study: 19772786
Drug: Intramuscular neridronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular neridronate (NE) 25 mg monthly
Study: 17722830
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Huang's Xiang Sheng Pills
Study: 8072255
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg body weight) administered intravenously 45 minutes before CM application.
Study: 8072255
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) administered intravenously 45 minutes before CM application.
Study: 31650662
Drug: individual internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: individual internet-based Mindfulness-Based Cognitive Therapy (eMBCT)
Study: 31650662
Drug: group-based face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: group-based face-to-face Mindfulness-Based Cognitive Therapy (MBCT)
Study: 31412947
Drug: Standard swallow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard swallow therapy (control group)
Study: 28587977
Drug: Straight implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straight implants (S, n=37)
Study: 28587977
Drug: Tilted implants
Normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilted implants (T, n=33)
Study: 25705800
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of hydrocortisone (0.2-0.3 mg/kg body weight/day) for 10 weeks
Study: 25705800
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of hydrocortisone (0.4-0.6 mg/kg body weight/day) for 10 weeks
Study: 25705800
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of hydrocortisone
Study: 23826093
Drug: 7.2 mg
Normalized name: lysine 7.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2 mg nicotine cartridges for 12 weeks (Group A)
Study: 23826093
Drug: 6-week 7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week 7.2 mg nicotine cartridges followed by 6-week 5.4 mg nicotine cartridges (Group B)
Study: 21950148
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg felodipine (Plendil)
Study: 21950148
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg felodipine (Plendil)
Study: 11555501
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no active treatment)
Study: 8151000
Drug: Buprenorphine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (4 or 8 mg/day, sublingual)
Study: 29206824
Drug: Sequential dilatation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential dilatation
Study: 26136585
Drug: High-polyphenol-content olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-polyphenol-content olive oil (HPCOO; 2.7 mg/kg)
Study: 26136585
Drug: Low-polyphenol-content olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-polyphenol-content olive oil (LPCOO; 366 mg/kg)
Study: 18303125
Drug: Atacicept (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (single subcutaneous or repeated every other week dose)
Study: 16977263
Drug: Continuous Subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Subcutaneous Insulin Infusion (CSII) with insulin lispro (n=20)
Study: 16977263
Drug: Intravenous Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Insulin Infusion (IVII) with regular insulin (n=13)
Study: 16977263
Drug: Intravenous Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Insulin Infusion (IVII)
Study: 12362961
Drug: Attention-placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-placebo group treatment (GT)
Study: 9746961
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vindesine, razoxane, and radiotherapy in 1 patient
Study: 2532681
Drug: Rinse volumes
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinse volumes of 2 ml, 5 ml, 10 ml, 15 ml, or 25 ml with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Study: 2532681
Drug: 0 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml rinse volume with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Study: 28955416
Drug: Amlodipine (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5mg once daily for 4 weeks)
Study: 28955416
Drug: Hydrochlorothiazide (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25mg once daily for 4 weeks)
Study: 25841237
Drug: Glycopyrronium (GLY)
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (GLY) 50 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Study: 25841237
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Study: 25841237
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Study: 21629270
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml camel milk in addition to usual care (diet, exercise, and insulin)
Study: 21629270
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (diet, exercise, and insulin)
Study: 16429457
Drug: Alpha tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha tocopherol (AT) supplementation (134 or 268 mg/day)
Study: 9357241
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg aspirin daily from day of positive ROT till 37 weeks of pregnancy
Study: 31211612
Drug: Citrus aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus aurantium aroma (neroli oil) inhalation, 30% essential oil in paraffin, administered three times a day
Study: 25365612
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg melatonin
Study: 22763212
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 2% lignocaine (lidocaine)
Study: 16444853
Drug: Enoxaparin monotherapy
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin monotherapy (1 mg/kg twice daily for 10‐18 days, then 1.5 mg/kg once daily until day 90)
Study: 16444853
Drug: Warfarin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin group (enoxaparin 1.0 mg/kg twice daily as a bridge to warfarin)
Study: 11830607
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus etoposide or paclitaxel (exact dosage and duration not specified)
Study: 10362172
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 2.5 mg
Study: 10362172
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 5 mg
Study: 10362172
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 10 mg
Study: 7543393
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (bisphosphonates, radioisotopes, local treatments)
Study: 20481050
Drug: Structural resonance
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural resonance electromagnetic therapy (SREMT) - 10-12 daily sessions of 43 minutes each on a Rematerp apparatus.
Study: 20481050
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the same medical and physiotherapeutic treatment without SREMT.
Study: 15105203
Drug: i.v. midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. midazolam (0.09 mg/kg)
Study: 9625132
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil extract (EPA 3.2 g, DHA 2.4 g)
Study: 30954341
Drug: High-nitrate salad
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-nitrate salad (twice daily for 10 days)
Study: 26721132
Drug: Medication (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (3 mg eszopiclone tablets orally before sleep, once every night for 6 weeks)
Study: 23882870
Drug: Light cigarette
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light cigarette (0.6 mg of nicotine, 8 mg of tar, and 9 mg of carbon monoxide)
Study: 23882870
Drug: Regular cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cigarette (0.9 mg of nicotine, 12 mg of tar, and 12 mg of carbon monoxide)
Study: 21729284
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg) administered orally at 21:00 h for five consecutive days
Study: 9221864
Drug: Topical nitroglycerine
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerine (0.2 percent glyceryl trinitrate ointment)
Study: 9221864
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic gel (lignocaine)
Study: 8213579
Drug: rt-PA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (10 mg bolus, followed by 50 mg in the first hour, and 20 mg/hour for the next 2 hours)
Study: 26898862
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid injection combined with acid-suppressive therapy (experimental group)
Study: 26898862
Drug: Acid-suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-suppressive therapy only (control group)
Study: 24529580
Drug: Silodosin 8-mg
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8-mg once-daily (QD)
Study: 24529580
Drug: Silodosin 4-mg
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 4-mg twice-daily (BID)
Study: 17499988
Drug: Laboratory and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory and hormone replacement studies
Study: 15072701
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) doses of 450 microg and 400 microg
Study: 10188768
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-10 (10 ng/mL)
Study: 7493146
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (60 mg/kg, i.v.)
Study: 30995433
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine + Exenatide (Iglar + GLP-1)
Study: 30995433
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (Iglar)
Study: 28026920
Drug: Naltrexone sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone sustained release (SR) 32 mg / Bupropion SR 360 mg + Comprehensive Lifestyle Intervention (CLI)
Study: 25827441
Drug: Empagliflozin 12.5
Normalized name: empagliflozin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 12.5 mg twice daily
Study: 25827441
Drug: Empagliflozin 5
Normalized name: empagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 5 mg twice daily
Study: 1696670
Drug: Nicardipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (4 doses: 1.25, 2.5, 5.0, and 10.0 mg administered by i.v. infusion over 40 min)
Study: 1245165
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg digoxin with 1100 mg magnesium-aluminium-silicate-hydrate (n=4)